ArticleNature immunology2024
Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy.
Open access · greenAbstract read
In one paragraph
Article in Nature immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed, 1 pooled it
26.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.
- Global research trends and focus on biomarkers in lung cancer immunotherapy: a comprehensive bibliometric insight and visualization analysis (2001-2025).Frontiers in immunology · 2026Pooled it
- Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results.Signal transduction and targeted therapy · 2025Trial
- Harnessing necroptosis via RIPK1 degradation to potentiate radio-immunotherapy in cervical cancer.Bioactive materials · 2027Article
- Efineptakin alfa (NT-I7) improves overall survival and induces immune niches in murine tumors.Genes & diseases · 2027Article
- CD8⁺ T Cell infiltration and spatial organization in cancer: mechanisms, barriers, and therapeutic strategies.Molecular biomedicine · 2026Review
- Spatiotemporal transcriptomics for tumour microenvironment remodelling in cancer progression and therapy.Clinical and translational medicine · 2026Review
- Emerging technologies in the spatial proteomics landscape.Analytical and bioanalytical chemistry · 2026Review
- Dendritic cell PD-L2 restrains intratumoral CD8bioRxiv : the preprint server for biology · 2026Article
- Epigenetic plus cytokine therapy induces stem-like CD8Journal for immunotherapy of cancer · 2026Article
- CD1d remodels the tumor-infiltrating myeloid populations controlling antitumor immunity.The Journal of experimental medicine · 2026Article
- Tertiary lymphoid structures in cancer: their development, composition, clinical prognosis, and the drivers of the anti-tumor responses.Molecular biomedicine · 2026Review
- Targeting cancer-intrinsic protein neddylation bypasses the loss of JAK/STAT signaling and overcomes acquired resistance to immunotherapy.Research square · 2026Article
- TSTScope Unifies Single-Cell Multi-Omics to Identify Functional T Cell States Predictive of Immunotherapy Response.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- An Integrated Spatial Multi-Omics Workflow for Sequential RNA and Protein Profiling in FFPE Tumor Tissue.Cancer research communications · 2026Article
- Tumor-Infiltrating mregDCs Restrain Anti-Tumor Immunity in Early Relapse HCC.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Single-nucleus multimodal spatial transcriptomics reveals spatial colocalization of neoantigen-expressing tumor cells and cognate T cells.Nature biotechnology · 2026Article
- Trimodal, uncertainty-guided whole-slide framework for genome-scale spatial expression and image-only virtual perturbation in cancer cohorts.Genome medicine · 2026Article
- A Circulating GPNMB-Based Multimodal Model Integrates Tumor-Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer.Cancer discovery · 2026Article
- Regulatory B-cell states in NSCLC immunotherapy resistance: mechanisms, spatial context and translational implications.Cancer immunology, immunotherapy : CII · 2026Review
53 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
37 authors at 6 institutions in 2 countries.
Jonathan H Chen *Massachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA. jhchen@broadinstitute.org.ORCID http://orcid.org/0000-0001-6074-9302
Linda T Nieman *Massachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA.
Maxwell Spurrell *Massachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA.
Vjola JorgjiMassachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA.
Liad ElmelechMassachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA.
Peter RichieriMassachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA.
Katherine H XuMassachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA.
Roopa MadhuHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6226-160X
Milan ParikhMassachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA.ORCID http://orcid.org/0000-0003-1336-7883
Izabella ZamoraBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Arnav MehtaMassachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA.
Christopher S NabelMassachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA.
Samuel S FreemanBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-8285-0057
Joshua D PirlBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Chenyue LuMassachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA.
Catherine B MeadorHarvard Medical School, Boston, MA, USA.
Jaimie L BarthDepartment of Pathology, MGH, Boston, MA, USA.
Mustafa SakhiCenter for Thoracic Cancers, MGH, Boston, MA, USA.
Alexander L TangBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Siranush SarkizovaBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Colles PriceVizgen, Cambridge, MA, USA.
Nicolas F FernandezVizgen, Cambridge, MA, USA.
George EmanuelVizgen, Cambridge, MA, USA.
Jiang HeVizgen, Cambridge, MA, USA.
Katrina Van RaayNanoString Technologies, Seattle, WA, USA.
Jason W ReevesNanoString Technologies, Seattle, WA, USA.
Keren YizhakDepartment of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
Matan HofreeBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Angela ShihDepartment of Pathology, MGH, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8945-5997
Moshe Sade-FeldmanMassachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA.ORCID http://orcid.org/0000-0002-0022-0287
Genevieve M BolandBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-7522-6173
Karin PelkaMassachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA.
Martin J AryeeBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-6848-1344
Mari Mino-KenudsonMassachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA.ORCID http://orcid.org/0000-0002-9092-2265
Justin F Gainor *Massachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA. jgainor@mgh.harvard.edu.ORCID http://orcid.org/0000-0001-8697-4081
Ilya Korsunsky *Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. ikorsunsky@bwh.harvard.edu.ORCID http://orcid.org/0000-0003-4848-3948
Nir Hacohen *Massachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA. nhacohen@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-2349-2656
Broad Institute · USHarvard University · USNanostring Technologies (United States) · USBrigham and Women's Hospital · USMGH Institute of Health Professions · USTechnion – Israel Institute of Technology · IL
Funding
(PQ3) The role of damaged DNA in inter-individual variation of tumor immunityR01CA208756 · NCI · BROAD INSTITUTE, INC. · PI HACOHEN, NIR · 2016 to 2020
$2.6MCancer Immunology Training GrantT32CA207021 · NCI · DANA-FARBER CANCER INST · PI WUCHERPFENNIG, KAI W · 2016 to 2020
$2.4MMalignant Cell Engagement in Immune Circuits of Human Microsatellite-stable and Microsatellite-instable Colorectal CancerR00CA259511 · NCI · J. DAVID GLADSTONE INSTITUTES · PI PELKA, KARIN · 2021 to 2023
$747kDelineating the mechanisms by which tumor immunity multicellular networks shape T cell stateK08CA273547 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI CHEN, JONATHAN HOWARD · 2023 to 2025
$680kNCI NIH HHS K08 CA273547NCI NIH HHS R00 CA259511NCI NIH HHS R01 CA208756NCI NIH HHS T32 CA207021
Abstract
The organization of immune cells in human tumors is not well understood. Immunogenic tumors harbor spatially localized multicellular 'immunity hubs' defined by expression of the T cell-attracting chemokines CXCL10/CXCL11 and abundant T cells. Here, we examined immunity hubs in human pre-immunotherapy lung cancer specimens and found an association with beneficial response to PD-1 blockade. Critically, we discovered the stem-immunity hub, a subtype of immunity hub strongly associated with favorable PD-1-blockade outcome. This hub is distinct from mature tertiary lymphoid structures and is enriched for stem-like TCF7
Indexed as
Lung NeoplasmsCD8-Positive T-LymphocytesChemokinesHumansImmunotherapyProgrammed Cell Death 1 ReceptorTumor MicroenvironmentChemokinesProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.